Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples
- PMID: 31237735
- DOI: 10.1002/uog.20383
Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples
Abstract
Objective: Direct chromosome preparations of chorionic villus samples (CVS) and cell-free DNA (cfDNA) testing both involve analysis of the trophoblastic cell lineage. The aim of this study was to compare the spectrum of rare autosomal trisomies (RATs) detected by these two approaches and assess the available information on their clinical significance.
Methods: Data from 10 reports on genome-wide cfDNA testing were pooled to determine which chromosomes were most frequently involved in RAT-positive cases, and pregnancy outcome information was reviewed. CVS information was obtained from an updated database of 76 102 consecutive CVS analyses performed over a period of 18 years at TOMA laboratory, in which trophoblastic and mesenchymal layers were analyzed and amniotic fluid cell analysis was recommended for RAT-positive cases. Chromosomes involved and presence of confined placental mosaicism, true fetal mosaicism and uniparental disomy (UPD) for imprinted chromosomes were assessed. Also evaluated were the frequency and types of RATs in products of conception.
Results: RATs were present in 634 of 196 662 (0.32%) cfDNA samples and 237 of 57 539 (0.41%) CVS trophoblast samples (P < 0.01). The frequency of RATs varied over 8-fold between the cfDNA reports. Confirmation of abnormality through amniocentesis was more likely when RATs were ascertained through cfDNA (14 of 151; 9.3%) than through CVS trophoblasts (seven of 237; 3.0%) (P < 0.01). In cfDNA-ascertained cases, trisomies 15, 16 and 22, which are associated with fetal loss, were identified proportionately more often. Of 151 cases with RAT identified by cfDNA and outcome information available, 41.1% resulted in normal live birth; 27.2% in fetal loss; 7.3% had phenotypic abnormality detected through ultrasound or other follow-up evaluation; 2.0% had a clinically significant UPD; and 14.6% had fetal growth restriction or low birth weight. All autosomes were involved in trisomies in products of conception; the most common RATs detected were trisomies 16, 22 and 15 with a frequency of > 9% each.
Conclusions: Although there are strong parallels between RATs ascertained through cfDNA analysis and direct chromosome preparation of CVS, caution is needed in applying conclusions from CVS analysis to cfDNA testing, and vice versa. RATs identified through genome-wide cfDNA tests have uncertain risks for fetal loss, growth restriction or fetal abnormality. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Keywords: cfDNA; chorionic villi; confined placental mosaicism; cytogenetic abnormalities; cytotrophoblasts; intrauterine growth restriction; miscarriage; non-invasive prenatal testing; trisomy; uniparental disomy.
Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Comment in
-
Genome-wide cfDNA testing of maternal blood.Ultrasound Obstet Gynecol. 2020 Jan;55(1):13-14. doi: 10.1002/uog.21945. Ultrasound Obstet Gynecol. 2020. PMID: 31894638 No abstract available.
Similar articles
-
Application of non-invasive prenatal testing in late gestation in a pregnancy associated with intrauterine growth restriction and trisomy 22 confined placental mosaicism.Taiwan J Obstet Gynecol. 2017 Oct;56(5):691-693. doi: 10.1016/j.tjog.2017.09.001. Taiwan J Obstet Gynecol. 2017. PMID: 29037560
-
Low-level mosaic trisomy 2 at amniocentesis in a pregnancy associated with positive NIPT and CVS results for trisomy 2, maternal uniparental disomy 2, perinatal progressive decrease of the aneuploid cell line, cytogenetic discrepancy between cultured amniocytes and uncultured amniocytes, intrauterine growth restriction and a favorable fetal outcome.Taiwan J Obstet Gynecol. 2023 Jul;62(4):571-576. doi: 10.1016/j.tjog.2023.05.002. Taiwan J Obstet Gynecol. 2023. PMID: 37407197
-
Confirmation of mosaicism and uniparental disomy in amniocytes, after detection of mosaic chromosome abnormalities in chorionic villi.Eur J Hum Genet. 2006 Mar;14(3):282-8. doi: 10.1038/sj.ejhg.5201564. Eur J Hum Genet. 2006. PMID: 16418738
-
Diagnostic testing after positive results on cell free DNA screening: CVS or Amnio?Prenat Diagn. 2021 Sep;41(10):1249-1254. doi: 10.1002/pd.6021. Epub 2021 Aug 25. Prenat Diagn. 2021. PMID: 34386984 Review.
-
Chromosomal mosaicism in chorionic villus sampling.Clin Perinatol. 1990 Dec;17(4):867-88. Clin Perinatol. 1990. PMID: 2286032 Review.
Cited by
-
Chromosomal mosaicism: Origins and clinical implications in preimplantation and prenatal diagnosis.Prenat Diagn. 2021 Apr;41(5):631-641. doi: 10.1002/pd.5931. Epub 2021 Mar 22. Prenat Diagn. 2021. PMID: 33720449 Free PMC article.
-
Cell-free DNA screening for rare autosomal trisomies and segmental chromosome imbalances.Prenat Diagn. 2022 Oct;42(11):1349-1357. doi: 10.1002/pd.6233. Epub 2022 Sep 22. Prenat Diagn. 2022. PMID: 36068932 Free PMC article.
-
Prenatal diagnosis of trisomy 8 mosaicism, initially identified by cffDNA screening.Mol Cytogenet. 2022 Sep 1;15(1):39. doi: 10.1186/s13039-022-00616-y. Mol Cytogenet. 2022. PMID: 36050777 Free PMC article.
-
Inherited unbalanced reciprocal translocation with 3q duplication and 5p deletion in a foetus revealed by cell-free foetal DNA (cffDNA) testing: a case report.Eur J Med Res. 2021 Jun 29;26(1):64. doi: 10.1186/s40001-021-00535-5. Eur J Med Res. 2021. PMID: 34187576 Free PMC article.
-
Ethical, Legal and Social Issues (ELSI) Associated with Non-Invasive Prenatal Testing: Reflections on the Evolution of Prenatal Diagnosis and Procreative Choices.Genes (Basel). 2021 Jan 30;12(2):204. doi: 10.3390/genes12020204. Genes (Basel). 2021. PMID: 33573312 Free PMC article. Review.
References
REFERENCES
-
- Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006; 169: 400-404.
-
- Flori E, Doray B, Gautier E, Kohler M, Ernault P, Flori J, Costa JM. Circulating cell-free fetal DNA in maternal serum appears to originate from cyto- and syncytio-trophoblastic cells. Case report. Hum Reprod 2004; 19: 723-724.
-
- Faas BH, de Ligt J, Janssen I, Eggink AJ, Wijnberger LD, van Vugt JM, Vissers L, Geurts van Kessel A. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert Opin Biol Ther 2012; 12 Suppl 1: S19-26.
-
- Ryan A, Hunkapiller N, Banjevic M, Vankayalapati N, Fong N, Jinnett KN, Demko Z, Zimmermann B, Sigurjonsson S, Gross SJ, Hill M. Validation of an Enhanced Version of a Single-Nucleotide Polymorphism-Based Non-invasive Prenatal Test for Detection of Fetal Aneuploidies. Fetal Diagn Ther 2016; 40: 219-223.
-
- Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ. Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. Prenat Diagn 2015; 35: 1243-1246.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources